GET DAILY SIGNALSCareCloud (CCLD) Delivers Record Q3 Profits with +54% Net Income Growth
Key Takeaways
- CareCloud reported third-quarter 2026 revenue of $33.7 million, up about 9% from $31.1 million a year earlier.
- GAAP net income reached a record $4.7 million, up 54% year over year, marking the company's 10th straight profitable quarter.
- GAAP earnings per share (EPS) hit a record $0.10, up from $0.04 a year ago, while adjusted EPS of $0.14 topped the $0.12 consensus estimate.
- Adjusted EBITDA rose 28% to a record $9.9 million.
- Management reaffirmed full-year 2026 guidance of $128 million to $132 million in revenue and GAAP EPS of $0.20 to $0.23.
- AI-driven claims automation cut manual claim touches by roughly 44% in three months, while the denial rate fell below 4%.
Earnings Context and Why It Matters
CareCloud's third-quarter report carries particular weight because it arrives at a pivotal moment in the company's transformation. The healthcare technology and revenue cycle management provider has been shifting toward higher-margin technology, compliance, and artificial intelligence offerings while moving away from lower-margin project-based services. After management called the second quarter a period of building, I wanted to see whether those efforts would produce clearer margin expansion. The results also provided a test of newer growth areas, such as enterprise AI development and the Empower compliance business, against a top line that has slowed as acquisition comparisons fade. I also checked this using Tickeron's AI Screener to compare the stock with others in the healthcare technology sector.
Reported Results
CareCloud posted its most profitable quarter in company history for the three months ended September 30, 2026. Revenue came in at $33.7 million, an increase of roughly 9% from $31.1 million in the prior-year period, modestly ahead of the $33.5 million consensus estimate. GAAP net income climbed 54% year over year to a record $4.7 million, and GAAP EPS reached a record $0.10, up from $0.04 a year earlier. Adjusted EPS of $0.14 beat the $0.12 consensus by about 16.7%. Adjusted EBITDA rose 28% to a record $9.9 million, reflecting a roughly 29% margin.
Gross margin expanded to 50.5% from 47.8% a year ago. Technology-enabled business solutions grew to $24.3 million from $21.6 million. Management reaffirmed full-year 2026 guidance of $128 million to $132 million in revenue, $29 million to $31 million in adjusted EBITDA, and GAAP EPS of $0.20 to $0.23.
Market Reaction and Investor Sentiment
Sentiment heading into the report had been cautious, with shares under pressure as revenue growth slowed from earlier quarters. The record profitability and margin expansion validated the efficiency story management has emphasized. The company's first quantified AI gains, including a denial rate below 4% versus roughly 8% a year ago and zero-touch claim processing at 84%, added substance to the operating narrative. Still, the unchanged full-year guidance and the implied modest fourth quarter left some investors unconvinced about near-term top-line momentum. Analysts' most recent rating on the stock is a Hold, with a $2.50 price target.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will focus on whether CareCloud can sustain its margin gains while re-accelerating revenue. Management reaffirmed its full-year 2026 outlook, which implies a seasonally softer fourth quarter at or below the third quarter's record profitability. That leaves limited room for upside surprise in the near term.
Several catalysts could shape the next few quarters. The company's enterprise AI platform work with KabaFusion produced its first development revenue in the third quarter, and management plans to report AI revenue separately once it reaches scale. A subscription-based compliance offering built on the Empower acquisition is expected to launch late in the fourth quarter, while AI prior authorization is now live with a pilot client and posting a 91% first-pass approval rate.
On the cost and balance-sheet side, the company continues to pay down the debt tied to its preferred stock redemption, reducing borrowings by roughly $7.4 million in under six months. Investors will watch whether these efficiency gains continue to flow to common shareholders and whether the shift toward higher-margin technology and compliance offerings can offset the drag from declining project-based professional services revenue.
Using AI Tools in My Research
One tool I rely on regularly for deeper market analysis is Tickeron's AI Screener. It helps me filter stocks and ETFs by technical patterns, fundamentals, trends, and AI-driven signals, making it easier to spot ideas across sectors like healthcare technology without manual effort. I have found it useful for comparing earnings movers and identifying potential setups efficiently.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for CCLD turns positive, indicating new upward trend
CCLD saw its Momentum Indicator move above the 0 level on November 04, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 81 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CCLD's RSI Oscillator exited the oversold zone, 28 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 63 cases where CCLD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for CCLD just turned positive on October 29, 2026. Looking at past instances where CCLD's MACD turned positive, the stock continued to rise in 38 of 46 cases over the following month. The odds of a continued upward trend are 83%.
Following a +3.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where CCLD advanced for three days, in 189 of 229 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
CCLD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CCLD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for CCLD entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.275) is normal, around the industry mean (4.886). P/E Ratio (30.857) is within average values for comparable stocks, (13.782). Projected Growth (PEG Ratio) (0.314) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.699) is also within normal values, averaging (6.065).
The Tickeron SMR rating for this company is 76 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. CCLD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CCLD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of medical billing and transcription services
Industry ServicestotheHealthIndustry
Advertisement